Lineage Cell Therapeutics (LCTX) Asset Utilization Ratio (2011 - 2026)

Lineage Cell Therapeutics' Asset Utilization Ratio history runs 16 years deep, the most recent figure standing at 0.13 for Q1 2026.

• On a quarterly basis, Asset Utilization Ratio rose 56.63% year-over-year to 0.13 in Q1 2026; TTM through Mar 2026 was 0.13, a 56.63% increase from a year earlier, with the FY2025 full-year figure at 0.13, up 45.39% from the prior year.
• Asset Utilization Ratio fell to 0.13 in Q1 2026 per LCTX's latest filing, from 0.14 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.47 in Q3 2022 and bottomed at 0.06 in Q2 2024.
• The 5-year median for Asset Utilization Ratio is 0.1 (2023), against an average of 0.16.
• Across the five-year window, Asset Utilization Ratio soared 3078.23% in 2022 and sank 82.87% in 2023, its largest moves.
• Year by year, Asset Utilization Ratio stood at 0.12 in 2022, then fell by 25.17% to 0.09 in 2023, then gained by 4.86% to 0.09 in 2024, then surged by 58.99% to 0.14 in 2025, then declined by 7.56% to 0.13 in 2026.
• Per Business Quant, the three latest LCTX Asset Utilization Ratio figures stand at 0.13 (Q1 2026), 0.14 (Q4 2025), and 0.12 (Q3 2025).